Diane Adair
Senior IP Counsel
Novartis
Where the IP Industry Comes Together
The Pharma and Biotech Patent Litigation Summit returns to Anantara Grand Hotel for 3 days practical discussion surrounding the leading patent litigation topics in Europe, with a compare and contrast method with jurisdictions further afield. Our internationally recognised summit will provide you with the necessary practical tools to both defend patent litigation challenges for your pharma and biotech product, whilst also maximising your litigation strategy to allow for successful IP protection. With the central case law and regulatory updates, this event is a must-attend for anyone with a focus on the European market and working within life science IP.
This year’s summit will host the cross-industry UPC Litigation Forum 2024 as a one-day meeting on 22nd January. This event will host the leading litigators and patent attorneys, in-house counsel and judges for a practical review of the early-stage experience of the UPC. At this event, you will network with leading figures in the industry and gain unique insights on the latest regulatory changes and case-law updates.
Download The Full Event SCHEDULE
Highlights For This Year Include:
- Form a holistic and practical UPC litigation strategy with a cross-industry case law review, a mock trial alongside leading judges and litigators and a pharma and biotech UPC strategy panel.
- Update your pharma and biotech patent litigation strategy with the latest regulatory developments and case law regarding the doctrine of equivalents, second medical use, preliminary injunctions and divisional patent practice.
- Develop a transatlantic understanding of patentability concerns with an Amgen vs Sanofi case law review and an industry-panel concerning the G2/21 EPO Board of Appeals decision.
- Form a global understanding of the patent litigation ecosphere with a panel of judges from the UK, EPO, USA and the UPC.
BOOK Your PLACE TODAY
A Snippet Of Our In-House Speaker Faculty
Mike Cottler
Global Head of LitigationAlvotech
Mathilde Rauline
Head of Greater Europe Patent LitigationSanofi
Stefanie Kies
Senior Director Intellectual PropertyPolpharma Biologics
Kristin Cooklin
Head of IPZentiva
Toni Santamaria
Vice President Intellectual PropertyAdalvo
Filip De Corte
Head of IPSyngenta
Corinna Sundermann
Senior Vice President Intellectual PropertyFresenius Kabi
Shohta Ueno
Assistant General Counsel - Dispute ResolutionRegeneron
Georgia Roussou
Senior Legal CounselWin Media
Naoise Gaffney
Vice President - Intellectual PropertyGH Research
Guido Pontremoli
Coporate IP Patent DirectorChiesi
Frank Landolt
Chief Counsel IP & LegalConfo Therapeutics
200+
Attendees
60+
Leading Top Speakers
10+
Jurisdiction-specific Roundtable Discussions
With a full slate of main-stage keynotes, breakout sessions, networking and more across three jam-packed days, you and your team will gain the connections and insights you need across three key pillars.
A Snippet Of Our Private Practice Speaker Faculty
Paul Inman
PartnerGowling
Eleanor Root
PartnerBird & Bird
Rob Cerwinski
PartnerGemini Law
Luca Pellicciari
PartnerTrevisan & Cuonzo
Daan De Lange
PartnerBrinkhof
Cecile Goy
PartnerAramis Law
Naomi Pearce
CEO and LawyerPearce IP
Agathe Michel-De-Cazotte
PartnerCarpmaels & Ransford
Tjibbe Douma
Partner, IP, AmsterdamBird & Bird
Peter van Schijndel
PartnerHoyng Rokh Monegier
Benjamin May
PartnerAramis
Otto Swens
PartnerVondst
Oya Yalvac
PartnerDERIS
Denis Schertenleib
PartnerSchertenleib Avocats
Our 2024 Speakers
Agathe Michel-De-Cazotte
Partner
Carpmaels & Ransford
Andras Kupecz
Honourable Judge
UPC Munich Central Division
Andreas Robinson
Senior Counsel Intellectual Property & Litigation
Amgen
Arjan Reijns
Legal Director Amsterdam
Pinsent Masons
Benjamin May
Partner
Aramis
Benjamin May was admitted to practice law in 2000 and further admitted to the panel of “Intellectual Property specialists” with the Bar Association. Practice head of IP at Aramis, Benjamin specializes in cross-border patent litigation with a focus on pharmaceuticals, medical devices and biotechs. The 7 attorneys of the IP team are all internationally trained and address a wide range of patent law matters (e.g. invalidity strategies, infringement, launching at risk, preliminary injunctions, licensing, R&D and consortium agreements). In 2023 the team was ranked amongst the leading patent litigation practices in France, and Benjamin as “leading individual” (Legal 500).
Brian O'Moore
Honourable Judge
Irish High Court
Cecile Goy
Partner
Aramis Law
Cécile Goy is a member of the Paris Bar focusing on international patent litigation, in particular in the life sciences sector. Before joining Aramis, Cécile worked with an international IP boutique and in-house in the legal department of a car manufacturer. Cécile has also completed an internship at the IP section of the Paris Court of Appeal. Cécile is the author of several articles, including on medical devices and digital therapeutics.
Chris Buntel
Co-Founder & CIPO
Tangibly
Chris Buntel is a US intellectual property attorney with over 20 years experience connecting innovation and intellectual property law. He is a co-founder and the CIPO of Tangibly. Chris is passionate about trade secrets – the “next big thing” in intellectual property evolution. While other forms of intellectual property have been well supported for years, people are just now realizing the huge need for trade secret management tools and education. He has a Ph.D. in Organic Chemistry from Stanford University, and J.D. in Law from University of Houston.
Christopher Freeth
Principal Associate
Gowling WLG
Clemens Heusch
Head of Global Disputes and Resolution
Nokia
Conrad Eckhardt
Vice President IP
Biotronik
Conrad practices in the IP field for more than 20 years and gained experience across various industries. Having started with Consumer Products at Procter & Gamble he moved on to Pharmaceuticals at Boehringer Ingelheim and is now active in the medical device field, first as Chief IP Counsel at Leica Biosystems and currently as Chief IP Counsel at Biotronik. Conrad is a European Patent Attorney and a European Patent Litigator and has patent litigation experience in Germany, the USA and China.
Corinna Sundermann
Senior Vice President Intellectual Property
Fresenius Kabi
Craig Svoboda
Global Head of IP
Albotech
Daan De Lange
Partner
Brinkhof
Denis Schertenleib
Partner
Schertenleib Avocats
Diane Adair
Senior IP Counsel
Novartis
Doug McCann
Principal
Fish & Richardson
Edgar Brinkman
Honourable Judge
UPC Local Division Hague
Mr. Brinkman finished a chemistry degree in 1993, specialising in biochemistry, and law degree in 1995 at Utrecht University in The Netherlands. After joining the bar that same year as a solicitor/barrister in Amsterdam focusing on patents and regulatory affairs, he was appointed judge at the Court of The Hague, IP department in 2002. He became a senior judge in 2007. He has been involved in many patent and other IP cases and speaks regularly on international conferences. He is co-editor of a leading Dutch IP magazine (BIE).
Eleanor Root
Partner
Bird & Bird
Eun-Joo Min
Director
WIPO Judicial Institute
Ewan Nettleton
Principal IP Counsel, Oncology Litigation
Novartis Pharma AG
Filip De Corte
Head of IP
Syngenta
Filip De Corte is Head of Intellectual Property at Syngenta Crop Protection, leading patent attorneys based in Switzerland, the UK, the US, The Netherlands and China. Filip joined Syngenta on October 1, 2013. Until then, he held the position of Chief IP Counsel Europe at Cargill (2008 – 2013). Before joining Cargill in 2008, he worked in the Johnson & Johnson patent department, working in Beerse with Janssen Pharmaceutica (1991-2004), New Brunswick (2004-2007), and Brussels (2007-2008). Filip has a Ph.D. in organic chemistry, he is a qualified European Patent Attorney and passed the US patent bar exam. He has the qualification of European Patent Litigation from the University of Strasbourg. He also has an MBA of the Vlerick School of Management. Filip taught patent law in Antwerp under the auspices of CEIPI (Université de Strasbourg) as well as at the University of Leuven in the IPR management course and is a lecturer in the CEIPI patent litigation course.
Filipe Pedro
Director of IP
BIAL
Frank Landolt
Chief Counsel IP & Legal
Confo Therapeutics
Frank Landolt is Chief Counsel, Intellectual Property and Legal at Confo Therapeutics, a privately held biopharmaceutical start-up based in Ghent, Belgium specializing in GPCR-targeted therapeutics.
After studying chemistry and law at the University of Leiden in the Netherlands, Frank worked for almost ten years on pharmaceutical and biotechological patents and licensing in private practice in the Netherlands, where his clients included major pharmaceutical companies as well as some of the top biotech firms and research institutions in the Netherlands.
Prior to joining Confo in 2018, Frank worked for fifteen years in Ablynx N.V. (now a wholly owned Sanofi company), where he was a member of the management team and headed an integrated IP and legal group of four lawyers and five patent professionals. At Ablynx, Frank was involved in negotiating Ablynx’s strategic partnerships and licensing deals with AbbVie, Boehringer-Ingelheim, MSD, Merck-Serono, Novartis, Novo Nordisk, Sanofi and Wyeth.
From 2000 to 2004, Frank was director of IP and legal counsel at Devgen N.V. (now part of Syngenta), another Ghent-based biotechnology company, where he was involved in negotiating Devgen’s strategic collaborations with Sumitomo, Monsanto and DuPont Pioneer.
Frank is a Dutch and European patent attorney, and also holds a degree in business law from the University of Antwerp. He is a member of the Dutch association of patent attorneys (where he is a tutor for the professional qualification course), EPI and LES Benelux (where he is involved in the LES Licensing Course). He is a regular speaker on a range of topics relating to IP and licensing in the (bio)pharmaceutical sector. Frank was named as one of Managing IP’s ‘Corporate IP stars’ for four years in a row (2015-2018).
Georgia Roussou
Senior Legal Counsel
Win Media
Guido Pontremoli
Coporate IP Patent Director
Chiesi
Currently employed as global Head of the IP department-Patent at Chiesi Farmaceutici SpA, managing and coaching a team of experienced patent attorneys, patent searchers and administrators, working on the protection, enforcement, litigation and/or opposition of the Chiesi IP, aligned with business decisions.
Before joining Chiesi, I worked in IP groups of big pharma companies (GSK Vaccine, and Bracco Imaging) as senior patent attorney responsible for all the IP aspects concerning some key R&D projects. I also had experience as patent counsel in private practices, dealing with pharma, chemical and bio entities.
Graduated in chemistry from the Univ of Milan, with a PhD in medicinal chemistry and a post-doc experience in USA, I am qualified EPA and chartered Italian patent attorney.
Jenny Davies
Partner
Gowling
Jenny Davies is a life sciences and patent specialist with a Masters in Biochemistry from Oxford. She provides strategic advice to help clients protect and exploit their R&D investment in the life sciences sector, medical device sector and the chemical industry. Her work regularly entails negotiating agreements to support her clients' research, development, manufacture and commercialisation, and protect their markets through the enforcement of patents.
Jenny delivers business-focused solutions across her unique practice area spanning patents and dispute resolution, transactions ranging from strategic licensing to highly complex collaborations and regulatory matters. She advises clients in all aspects of patent enforcement, from technical analysis and global strategy to leading UK litigation and EPO oppositions.
Given the commercial and practical value of the assets Jenny protects, her approach combines precision and detail with a commercial mindset and sector-led solutions. Clients praise her "endless determination", "formidable intellect" and are "deeply impressed" with her "unusual capacity to think creatively".
Her work highlights include leading ground-breaking patent litigation up to the UK Court of Appeal to achieve a novel form of "Arrow declaration" for Fujifilm Kyowa Kirin and advising AstraZeneca across a range of high value and complex transactions: its collaboration with the University of Oxford (COVID-19 vaccine); two $6 billion oncology collaborations with Daiichi Sankyo; an $8.5 billion oncology deal with Merck; and a $300 million oncology deal with Genzyme (Caprelsa).
Jenny is a member of the BioIndustry Association's IP Advisory Committee, and SPC and exclusivities committee, and a regular speaker on patent litigation and strategy.
Jiri Slavik
Director of IP
Adalvo
John Cox
Partner
Barnes & Thornburg
With deep knowledge of issues facing the life sciences industry, John Cox counsels clients regarding their worldwide intellectual property rights and represents their patent interests when litigation arises, particularly regarding pharmaceutical, chemical, and biotechnology matters. John takes his role in protecting these important assets of life science innovators very seriously while approaching each matter with enthusiasm.
Through his ability to communicate effectively and succinctly, John advises on, develops, and carries out global IP strategies for the benefit of innovative companies, his clients, who are focused on developing core assets that save and improve the lives of patients. John enjoys leveraging his unique ability to put together targeted and enduring teams for each matter – paying close attention to each person’s strengths and skillsets and how they fit with one another, alongside his highly specialized experience and thoughtful and responsive nature.
John is intimately familiar with the pharmaceutical industry, having dealt with patent and IP subject matter ranging from brain chemistry, the gastrointestinal system, drug delivery systems and treatments of rare diseases and cancer to medical diagnostic methods, the generation of biofuel using bacteria, and processes for manufacturing chemicals and pharmaceutical products. He also has almost two decades of experience in Abbreviated New Drug Application (ANDA) cases, including pre-litigation investigations.
John offers guidance from the first step of a matter through to resolution, including all aspects of litigation. He has extensive experience related to discovery and motion practice, as well as in developing offensive and defensive strategies. He is well versed in dealing with complex subject matter and technical witnesses, such as inventors and experts.
John adeptly helps clients navigate the crossroads of foreign business practices and the complexities of U.S. patent practice, having worked with foreign pharmaceutical, chemical, and biotechnology companies throughout his career.
Jonathan Singer
Principal
Fish & Richardson
Jon is a principal in the firm’s San Diego office and heads the life sciences litigation practice. He appears regularly as lead counsel in his matters and handles all aspects of litigation, including leading jury and bench trials, trying cases to administrative and arbitration panels and conducting briefing and arguments before the U.S. Courts of Appeals and the PTAB. Jon is annually named one of the nation’s finest life sciences trial attorneys and is an expert in proceedings under the Hatch-Waxman Act. His clients consistently praise his innovative and ground-breaking work and over the past two decades, he has successfully handled dozens of cases covering all aspects of the life sciences.
Kathleen Fox Murphy
Partner
EIP
Karin Pramberger
Intellectual Property Director
Polpharma Group
Karin has been Intellectual Property Director at the Polpharma Group since April 2018. She is responsible for all patent and trade mark related activities. Prior to joining the Polpharma Group, Karin was Head of IP of Medichem, Spain, and worked in various positions within the patent department of Teva, Barr and Pliva. She spent 7 years in a law firm in Vienna, Austria, where she became European and Austrian patent and trade mark attorney. She studied Biotechnology in Vienna, Austria, and at the Ecole Nationale Supérieure de Chemie de Paris, France. In 2017 she graduated with an LLB from the University of London. Since 2005 she has been a tutor at CEIPI, University of Strasbourg, for the pre-exam and the C-part of the European Qualifying Exam.
Katherine A. Helm
Partner
Dechert (USA)
Katherine A. ("Kassie") Helm, Ph.D., is a first-chair counsel who represents leading innovator pharmaceutical and biotechnology companies in patent litigation and patent-adjacent litigation matters. Her doctorate in neuroscience allows her to leverage her scientific background alongside her legal acumen to develop and execute winning positions for life sciences companies in all phases of district court litigation and Federal Circuit and other circuit court appeals, and before the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office. She has prevailed in high-stakes cases representing life sciences companies as both plaintiff and defendant in patent infringement actions and as both petitioner and patent owner in Post Grant Reviews (PGRs) and Inter Partes Reviews (IPRs) at the PTAB, as well as in interferences and appeals. Dr. Helm is fluent in French and frequently involved in patent disputes with multijurisdictional aspects, including post-issuance patent proceedings around the globe. She regularly plays a leading role in coordinated global patent disputes involving co-pending ex-U.S. proceedings involving biologic therapeutics in the European national courts in patent revocation, nullity and infringement actions, as well as in opposition proceedings before the European Patent Office (EPO) and on appeal before the Technical Boards. Dr. Helm and her team have also been successful in utilizing U.S. discovery mechanisms under 28 USC § 1782 to assist with foreign patent litigations and EPO proceedings.
Dr. Helm is a founder of the New York chapter of ChIPs (Chiefs of Intellectual Property), a global nonprofit organization dedicated to advancing and connecting women in law, technology and regulatory policy. She is also a founder of the Lead Counsel Summit, a forthcoming force in the industry for female lead trial counsel. Dr. Helm currently serves as a Vice Chair on the Federal Circuit Bar Association’s Bench & Bar Planning Committee. In 2021, Dr. Helm was individually recognized as a winner of Dechert’s Samuel E. Klein Pro Bono Awards, for her work on behalf of military veterans before the U.S. Court of Appeals for the Federal Circuit. In 2023, Dr. Helm was appointed Vice Chair of the Patent Litigation Committee of the American Bar Association Section of Intellectual Property Law (ABA-IPL) for the 2023-2024 bar year and appointed to the ABA-IPL’s Task Force on Improving the Durability and Reliability of the Patent Right for the same period. Dr. Helm has been recognized by numerous publications for her expertise, including by IAM Patent 1000, where in 2023, she was described as someone who “excels in biologics litigation and is a go-to for some of the industry’s major players to handle their most important disputes.”
Kit Carter
Head of IP Litigation
Sandoz
Kristin Cooklin
Head of IP
Zentiva
Laetitia Szaller
General Counsel
AM Pharma
Laetitia has over 20 years’ experience in multiple sectors, including 15 in the pharmaceuticals and medical device industry, leading and managing complex multi-jurisdiction operations including global multi-million M&A deals. Prior to joining AM-Pharma in April 2020 as General Counsel, VP Business Development and Corporate Secretary, she was at UCB as global Associate General Counsel BD, M&A and Antitrust. Prior to UCB, Laetitia was Legal Director, Emerging Markets EMEA, Central European Region and Benelux at Zoetis (Pfizer former animal health division), and has also led the EMEA legal department for the Abbott Vascular division at Abbott. She also held global positions at the Carlson Rezidor Hotel Group and at the automotive division (Wabco) at American Standard. Laetitia is a qualified lawyer in both the UK and Belgium, with extensive international experience, regularly speaking at various legal conferences.
Luca Pellicciari
Partner
Trevisan & Cuonzo
Martina Hufnal
Patent Trial Lawyer
Fish and Richardson
Marc Holtorf
Partner
Pinsent Masons
Mathilde Rauline
Head of Greater Europe Patent Litigation
Sanofi
Mathilde is a European patent attorney, is qualified as a French patent attorney, and is admitted to the Paris bar.
She is head of Greater Europe patent litigation at Sanofi, after having been a patent litigator in private practice (mostly in the pharmaceutical field), and a patent attorney in the industry (Sanofi, Nestlé).
She has extensive experience in pharmaceutical and life-science patent litigation in France, at the EPO, in Europe, and in Eurasia.
Her expertise also comprises contractual matters, settlements, regulatory aspects, and the SPC regulation.
Maximilian Haedicke
Honourable Judge
UPC Court of Appeals
Mike Cottler
Global Head of Litigation
Alvotech
Naoise Gaffney
Vice President - Intellectual Property
GH Research
Naomi Pearce
CEO and Lawyer
Pearce IP
Naomi Pearce is CEO, Executive Lawyer, Patent & Trade Mark Attorney, and Founder of Pearce IP which commenced in 2017 and won 2021 “IP Team of the Year” at the Australian Law Awards. With a science background in biology, Naomi has been serving life sciences clients for 25 years. Among other awards, Naomi is 2023 Lawyers Weekly “IP Partner of the Year”, the 2022 Lexology Client Choice Award winner (Life Sciences), 2022 Women in Business Law Asia Pacific “Patent Lawyer of the Year”, 2022 Australasian Lawyer “Most Influential Lawyer”, is ranked in IAM Patent 1000, and a MIP “Patent Star”.
Owen Swens
Partner
Vondst
Otto Swens
Partner
Vondst
Oya Yalvac
Partner
DERIS
Oya is a Turkish and European Patent Attorney with a background in molecular biology and genetics.
She has worked in the pharmaceutical industry as an in-house patent attorney for more than 10 years.
She is specialized in patent litigation and freedom to operate analysis.
Patricia Rombach
Honourable Judge
UPC Court of Appeals
Paul Inman
Partner
Gowling
With more than 25 years' experience of litigating intellectual property (IP) disputes both within the UK and internationally, Paul Inman works with companies ranging from small start-ups to major multi-national corporations. He specialises in the life sciences sector, which includes acting on high-profile pharmaceutical patent infringement cases in the UK Patents Court.
Paul provides life science businesses with commercial advice from an international outlook. His specialist experience ideally places him to provide this expertise and client care, with the ultimate aim of delivering well-rounded advice and guidance to ensure the best possible outcome.
As well as litigating in the English courts, he has co-ordinated and advised on IP and regulatory litigation matters across the globe; from all over Europe and the US, to as far afield as Asia, South Africa, Australia and New Zealand.
Successfully guiding clients through the maze of litigation is where Paul's strength lies, having now been involved over 25 years of litigation in cases leading to more than 40 reported judgments. These range from the tribunals of the UK Patent Office up to the House of Lords, European Patent Office and European Court of Justice.
Paul also has a degree in Molecular Biology and Biochemistry and during his professional career has established an outstanding reputation in the market. He is distinguished in the 2023 edition of IAM Patent 1000: The World's Leading Patent Professionals, ranked individually for both IP law and life sciences law in the peer review publication 'Best Lawyers® in the UK' and recognised in several categories within Chambers & Partners UK 2023.
Peter van Schijndel
Partner
Hoyng Rokh Monegier
Petri Rinkenen
Honourable Judge
UPC Helsinki Local Division
Mr. Petri Rinkinen works as a legally qualified judge in the Unified Patent Court (UPC). He is the presiding judge in the Helsinki local division. He has worked as a judge from September 2013 in the exclusive Finnish IP-court, the Market Court in Helsinki, Finland focusing on IPR-matters, especially to patent cases. Prior to joining the court he has worked as an attorney-at-law since mid 1990’s focusing on IPR-matters. He is a frequent lecturer in IPR-matters.
Pierluigi Perrotti
Honourable Judge
UPC Local Division Milan
Rob Cerwinski
Partner
Gemini Law
Roberto Rodrigues
Partner
Licks Attorneys
Rob Rodrigues manages high-stakes business and IP disputes in Brazil. He assists Fortune 500 and startup companies in matters requiring complex technical ability with a strategic approach, managing patent portfolios of the largest life sciences companies across the globe. His understanding of the Brazilian market makes him a "go-to" lawyer when dealing with enforcement measures.
Rob earned an LLM from Stanford Law School and is regularly recognized by leading publications like The Legal 500, IAM, and IP Stars, with clients noting that he “combines strong technical skills and a flair for complexity with commercial awareness, pragmatism, and sound judgment.” His clients praise his technical skills, his ability to perform under pressure, and his outstanding leadership in the local community.
Sergio Napolitano
General Counsel
Medicines for Europe
Shohta Ueno
Assistant General Counsel - Dispute Resolution
Regeneron
Stefanie Kies
Senior Director Intellectual Property
Polpharma Biologics
Stefan Luginbuehl
Head of Department European Legal Affairs
European Patent Office (EPO)
Stefan Luginbuehl, PhD, lawyer, is Head of the Department European Legal Affairs (Dep 5222) at the European Patent Office where he is dealing with a wide range of patent law and patent litigation related subjects, with emphasis on the implementation of the EU unitary patent package into the existing European patent system.
He participated in several Diplomatic and Intergovernmental Conferences on the reform of the European patent system and the international litigation system. He is a lecturer in different universities and is the author and editor of several books and articles on patent procedure and patent litigation in Europe and China.
Sufiyah Sulaiman
Senior Patent Manager Patent Litigation
STADA
Sufiyah Sulaiman is an attorney-at-law with a master’s degree in science. As an in-house patent litigation counsel of generic pharma giants, she has been managing their patent litigation and product launch-at-risk globally. At the moment, she is a senior manager (patent litigation) at STADA (Arzneimittel) AG, before that she was the Global IP litigation counsel for Sandoz (International GmbH) and, IP and regulatory litigation counsel for Mylan (now Viatris).
Takanori Abe
Managing Partner
ABE & PARTNERS
Mr. ABE is an Attorney-at-Law, admitted in both Japan and New York. He is currently a Guest Professor of Osaka University Graduate School of Medicine and formerly a lecturer of The University of Tokyo Graduate School of Medicine and Faculty of Medicine. He is an arbitrator in Japan and sit on various positions in Japanese medical/pharmaceutical societies.
Mr. ABE works in wide areas of international and corporate matters with a focus on intellectual property law and international commerce. The patent litigations that he has participated covers the fields of pharmaceuticals, chemistry, electronics and machinery, which involve advanced technology such as biotechnology, semiconductors, etc., and which are cross-border matters. He has extensive experience on representing and advising multinational and domestic clients in pharmaceutical industry and is currently involved in the drastic battle between brands and also the one between brands and generics. He also has experience in trademark, copyright and unfair competition litigation.
For Mr. ABE’s detail information and activities, please visit www.abe-law.com or email to: [email protected]
Tjibbe Douma
Partner, IP, Amsterdam
Bird & Bird
Toni Santamaria
Vice President Intellectual Property
Adalvo
Toni has been leading the Intellectual Property team at Adalvo since 2021. He has more than 20 years of experience in different pharmaceutical companies where he has been involved in developing and implementing complex patent and data exclusivity litigation strategies for several generics and added value products, including leading parallel litigation cases in multiple European countries. He also has experience in patent and trademark prosecution.
Toni qualified as European Patent Attorney in 2010 and holds a PhD in Organic Chemistry.
Zack Mummery
Partner
Reddie & Grose
Zack is a partner at Reddie & Grose and is a UK and European patent attorney based in London.
Zack assists large multinational corporations, SMEs and start-ups operating at the cutting edge of chemistry and pharmaceutical technologies.
Zack has a wealth of experience drafting new patent applications and managing large patent portfolios covering developed and emerging markets. Zack regularly provides clear commercially focussed advice on global patent strategies, utilising patent protection and managing the risk posed by third party patent rights.
Zack also has experience supporting clients through funding rounds, assisting clients with investor due diligence and he has provided IP support for a number of large deals including a multimillion dollar public offering.
Agenda
"The event provided an exceptionally strong palette of issues relevant for practitioners in the pharma/biotech patent litigation field. The panels were of high quality and I particularly appreciated the practical and transparent insights of industry speakers and UPC judges. The venue and logistics were also excellent, a really high quality conference overall." - Danubia Legal
Our conference programme features the latest insights from the industry’s top companies and key thoughts-leaders, tackling the most pertinent issues and trends in the industry.
With three stages of content, you’ll be able to tailor your perfect agenda to meet your specific business needs – allowing you & your team to gain the tangible intel you need to fast-track your product development over the next 12 months.
Portfolio Testimonials
I had two goals in attending the litigation conference, and both were accomplished. First, network:
in just two short days, I met a number of lawyers who I may call to one day for advice or just to chat.
Second, learn: the presentations and roundtables provided just the right depth for someone like me, a
US-trained lawyer, who wanted to learn more about ex-US IP law and litigation. I am grateful for having
the opportunity to speak at the conference, and I look forward to attending others to come.
Mike Cottler, Head of Global Litigation, Alvotech
It is always great to attend conferences wherein both in house and law firm speakers are there, in addition when we can get generic and innovators views
Aude Veinante, European Patent Attorney, Lavoix
Great topics and high quality speakers. Not to forget about the great networking opportunities face to face. I truly enjoyed the event.
Adrian Spillmann, Director of Intellectual Property, Valneva
Good, relevant and practical topics, with good interaction between attendees and frank but respectful exchanges of views.
Daniel Lim, Partner, Kirkland & Ellis
Package
Sending Your Team? Group Discounts Available!
Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates
Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off
If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920
We accept the following cards through Stripe:
Ticket price will increase in
— —
Friday, July 28, 2023 to Friday, August 18, 2023
Tier 1 - In-House
€799
Pre-Launch Rate (Register Before 18 August & Save €800)
Exclusively for Pharma and Biotech
2 Day In-Person Conference Pass
You can add our pre-day event as an add-on during registration
Saturday, August 19, 2023 to Saturday, September 30, 2023
Tier 1 - In-House
€999
Super Super Early Bird rate (Register Before 29 September & Save €600)
Exclusively for Pharma and Biotech
2 Day In-Person Conference Pass
You can add our pre-day event as an add-on during registration
Sunday, October 1, 2023 to Friday, November 3, 2023
Tier 1 - In-House
€1199
Super Early Bird rate (Register Before 3 November & Save €400)
Exclusively for Pharma and Biotech
2 Day In-Person Conference Pass
You can add our pre-day event as an add-on during registration
Saturday, November 4, 2023 to Friday, December 8, 2023
Tier 1 - In-House
€1399
Early Bird rate (Register Before 8 December & Save €200)
Exclusively for Pharma and Biotech
2 Day In-Person Conference Pass
You can add our pre-day event as an add-on during registration
Saturday, December 9, 2023 to Wednesday, January 24, 2024
Tier 1 - In-House
€1599
Standard Rate
Exclusively for Pharma and Biotech
2 Day In-Person Conference Pass
You can add our pre-day event as an add-on during registration
Saturday, July 29, 2023 to Friday, August 18, 2023
Tier 2 - Law Firms
€1699
Pre-Launch Rate (Register Before 18 August & Save €1000)
Exclusively for Law firms focusing on Life Sciences & Intellectual Properties Providers Pricing
2 Day In-Person Conference Pass
You can add our pre-day event as an add-on during registration
Saturday, August 19, 2023 to Saturday, September 30, 2023
Tier 2 - Law Firms
€1899
Super Super Early Bird rate (Register Before 29 September & Save €800)
Exclusively for Law firms focusing on Life Sciences & Intellectual Properties Providers Pricing
2 Day In-Person Conference Pass
You can add our pre-event workshop as an add-on during registration
Sunday, October 1, 2023 to Friday, November 3, 2023
Tier 2 - Law Firms
€2299
Super Early Bird rate (Register Before 3 November & Save €400)
Exclusively for Law firms focusing on Life Sciences & Intellectual Properties Providers Pricing
2 Day In-Person Conference Pass
You can add our pre-event workshop as an add-on during registration
Saturday, November 4, 2023 to Friday, December 8, 2023
Tier 2 - Law Firms
€2499
Early Bird rate (Register Before 8 Decemeber & Save €200)
Exclusively for Law firms focusing on Life Sciences & Intellectual Properties Providers Pricing
2 Day In-Person Conference Pass
You can add our pre-event workshop as an add-on during registration
Saturday, December 9, 2023 to Wednesday, January 24, 2024
Tier 2 - Law Firms
€2699
Standard Rate
Saturday, July 29, 2023 to Friday, August 18, 2023
Tier 3 - Vendors
€2199
Pre-Launch Rate (Register Before 18 August & Save €800)
Exclusively for Solution Providers
2 Day In-Person Conference Pass
You can add our pre-event workshop as an add-on during registration
Saturday, August 19, 2023 to Saturday, September 30, 2023
Tier 3 - Vendors
€2399
Super Super Early Bird rate (Register Before 29 September & Save €600)
Exclusively for Solution Providers
2 Day In-Person Conference Pass
You can add our pre-event workshop as an add-on during registration
Sunday, October 1, 2023 to Friday, November 3, 2023
Tier 3 - Vendors
€2599
Super Early Bird rate (Register Before 3 November & Save €400)
Exclusively for Solution Providers
2 Day In-Person Conference Pass
You can add our pre-event workshop as an add-on during registration
Saturday, November 4, 2023 to Friday, December 8, 2023
Tier 3 - Vendors
€2799
Early Bird rate (Register Before 8 December & Save €200)
Exclusively for Solution Providers
2 Day In-Person Conference Pass
You can add our pre-event workshop as an add-on during registration
Saturday, December 9, 2023 to Wednesday, January 24, 2024
Tier 3 - Vendors
€2999
Standard Rate
Exclusively for Solution Providers
2 Day In-Person Conference Pass
You can add our pre-event workshop as an add-on during registration
Friday, July 28, 2023 to Monday, January 22, 2024
UPC Forum 2024 (22 January)
€899
Develop a Pan-European litigation strategy Industry-led panel sessions focusing patent value and the UPC from a cross-industry perspective
Understand the decision making process of the people behind the new system with a cross-industry judicial panel session
Gain a practical and in-depth understanding of UPC litigation practice with a mock trial focusing on the central themes of the new court
Preparing registration...
Register Your Interest for 2024
HIGHLIGHTS FOR 2024
- Form a holistic and practical UPC litigation strategy with a cross-industry case law review, a mock trial alongside leading judges and litigators and a pharma and biotech UPC strategy panel.
- Update your pharma and biotech patent litigation strategy with the latest regulatory developments and case law regarding the doctrine of equivalents, second medical use, preliminary injunctions and divisional patent practice.
- Develop a transatlantic understanding of patentability concerns with an Amgen vs Sanofi case law review and an industry-panel concerning the G2/21 EPO Board of Appeals decision.
- Form a global understanding of the patent litigation ecosphere with a panel of judges from the UK, EPO, USA and the UPC.
From time to time, we would like to contact you about our products and services, as well as other content that may be of interest to you. If you consent to us contacting you for this purpose, please tick "YES!".
Subject Access Requests: If you would like a copy of the data/information we hold about you, please email [email protected].
User Deletion Request: If you wish to have your information that is held by Kisaco Research deleted, please email [email protected].
For more information on Kisaco Research policy and procedures, please visit our Privacy Policy.
By clicking submit below, you consent to allow Kisaco Research to store and process the personal information submitted above to provide you the content requested.
Download Today
Life Sciences Patent Advisory Board
Dr. Leslie Fischer
Principal Patent Attorney
Sandoz
Leslie Fischer is a Principal Patent Attorney at Sandoz, who focuses on global IP strategy for biosimilars. Before joining Sandoz, Leslie was a patent attorney at Novartis Pharmaceuticals, where she worked for over a decade developing global patent portfolios for biologicals. Before joining the Novartis group, Leslie was an associate at Fitzpatrick Cella (NY) (now Venable). Leslie holds a J.D. from Rutgers University and a Ph.D. in Biochemistry from Thomas Jefferson University. Her scientific work appears in JCB, JBC, and Osteoarthritis & Cartilage. She speaks frequently at patent-related events and is an adjunct professor at Seton Hall Law School.
Christof Bull
Assistant General Patent Counsel
UCB
Mathilde Rauline
Head of Greater Europe Patent Litigation
Sanofi
Mathilde is a European patent attorney, is qualified as a French patent attorney, and is admitted to the Paris bar.
She is head of Greater Europe patent litigation at Sanofi, after having been a patent litigator in private practice (mostly in the pharmaceutical field), and a patent attorney in the industry (Sanofi, Nestlé).
She has extensive experience in pharmaceutical and life-science patent litigation in France, at the EPO, in Europe, and in Eurasia.
Her expertise also comprises contractual matters, settlements, regulatory aspects, and the SPC regulation.
Lorenz Kallenbach
Senior Corporate Patent Counsel (Director)
Merck
Lorenz Kallenbach is a senior corporate patent counsel in the healthcare division of Merck KGaA. He is responsible for defining and executing the IP strategy for innovator projects. Including the assessment of the IP landscape, coordination of worldwide patent litigation, and portfolio development.
Before joining Merck, Lorenz worked in private practice. He is qualified as a German and European patent attorney.
Lorenz studied biochemistry and received a Ph.D. in the field of epigenetics.
Stephan Kutik
Director, Intellectual Property
Genevant Sciences GmbH
Ewan Nettleton
Principal IP Counsel, Oncology Litigation
Novartis Pharma AG
Mike Cottler
Global Head of Litigation
Alvotech
Tessa M. Malamud-Cohen
Director, Patents, Global Intellectual Property
Ferring Pharmaceuticals
Paki Banky
Senior IP Counsel (IP Lead Cell & Gene)
Novartis
Corinna Sundermann
Senior Vice President Intellectual Property
Fresenius Kabi
Frank Landolt
Chief Counsel IP & Legal
Confo Therapeutics
Frank Landolt is Chief Counsel, Intellectual Property and Legal at Confo Therapeutics, a privately held biopharmaceutical start-up based in Ghent, Belgium specializing in GPCR-targeted therapeutics.
After studying chemistry and law at the University of Leiden in the Netherlands, Frank worked for almost ten years on pharmaceutical and biotechological patents and licensing in private practice in the Netherlands, where his clients included major pharmaceutical companies as well as some of the top biotech firms and research institutions in the Netherlands.
Prior to joining Confo in 2018, Frank worked for fifteen years in Ablynx N.V. (now a wholly owned Sanofi company), where he was a member of the management team and headed an integrated IP and legal group of four lawyers and five patent professionals. At Ablynx, Frank was involved in negotiating Ablynx’s strategic partnerships and licensing deals with AbbVie, Boehringer-Ingelheim, MSD, Merck-Serono, Novartis, Novo Nordisk, Sanofi and Wyeth.
From 2000 to 2004, Frank was director of IP and legal counsel at Devgen N.V. (now part of Syngenta), another Ghent-based biotechnology company, where he was involved in negotiating Devgen’s strategic collaborations with Sumitomo, Monsanto and DuPont Pioneer.
Frank is a Dutch and European patent attorney, and also holds a degree in business law from the University of Antwerp. He is a member of the Dutch association of patent attorneys (where he is a tutor for the professional qualification course), EPI and LES Benelux (where he is involved in the LES Licensing Course). He is a regular speaker on a range of topics relating to IP and licensing in the (bio)pharmaceutical sector. Frank was named as one of Managing IP’s ‘Corporate IP stars’ for four years in a row (2015-2018).
Guido Pontremoli
Coporate IP Patent Director
Chiesi
Currently employed as global Head of the IP department-Patent at Chiesi Farmaceutici SpA, managing and coaching a team of experienced patent attorneys, patent searchers and administrators, working on the protection, enforcement, litigation and/or opposition of the Chiesi IP, aligned with business decisions.
Before joining Chiesi, I worked in IP groups of big pharma companies (GSK Vaccine, and Bracco Imaging) as senior patent attorney responsible for all the IP aspects concerning some key R&D projects. I also had experience as patent counsel in private practices, dealing with pharma, chemical and bio entities.
Graduated in chemistry from the Univ of Milan, with a PhD in medicinal chemistry and a post-doc experience in USA, I am qualified EPA and chartered Italian patent attorney.
Kristin Cooklin
Head of IP
Zentiva
Toni Santamaria
Vice President Intellectual Property
Adalvo
Toni has been leading the Intellectual Property team at Adalvo since 2021. He has more than 20 years of experience in different pharmaceutical companies where he has been involved in developing and implementing complex patent and data exclusivity litigation strategies for several generics and added value products, including leading parallel litigation cases in multiple European countries. He also has experience in patent and trademark prosecution.
Toni qualified as European Patent Attorney in 2010 and holds a PhD in Organic Chemistry.
Shohta Ueno
Assistant General Counsel - Dispute Resolution
Regeneron
Dr. Leslie Fischer
Principal Patent Attorney
Sandoz
Leslie Fischer is a Principal Patent Attorney at Sandoz, who focuses on global IP strategy for biosimilars. Before joining Sandoz, Leslie was a patent attorney at Novartis Pharmaceuticals, where she worked for over a decade developing global patent portfolios for biologicals. Before joining the Novartis group, Leslie was an associate at Fitzpatrick Cella (NY) (now Venable). Leslie holds a J.D. from Rutgers University and a Ph.D. in Biochemistry from Thomas Jefferson University. Her scientific work appears in JCB, JBC, and Osteoarthritis & Cartilage. She speaks frequently at patent-related events and is an adjunct professor at Seton Hall Law School.
Christof Bull
Assistant General Patent Counsel
UCB
Mathilde Rauline
Head of Greater Europe Patent Litigation
Sanofi
Mathilde is a European patent attorney, is qualified as a French patent attorney, and is admitted to the Paris bar.
She is head of Greater Europe patent litigation at Sanofi, after having been a patent litigator in private practice (mostly in the pharmaceutical field), and a patent attorney in the industry (Sanofi, Nestlé).
She has extensive experience in pharmaceutical and life-science patent litigation in France, at the EPO, in Europe, and in Eurasia.
Her expertise also comprises contractual matters, settlements, regulatory aspects, and the SPC regulation.
Lorenz Kallenbach
Senior Corporate Patent Counsel (Director)
Merck
Lorenz Kallenbach is a senior corporate patent counsel in the healthcare division of Merck KGaA. He is responsible for defining and executing the IP strategy for innovator projects. Including the assessment of the IP landscape, coordination of worldwide patent litigation, and portfolio development.
Before joining Merck, Lorenz worked in private practice. He is qualified as a German and European patent attorney.
Lorenz studied biochemistry and received a Ph.D. in the field of epigenetics.
Stephan Kutik
Director, Intellectual Property
Genevant Sciences GmbH
Ewan Nettleton
Principal IP Counsel, Oncology Litigation
Novartis Pharma AG
Mike Cottler
Global Head of Litigation
Alvotech
Tessa M. Malamud-Cohen
Director, Patents, Global Intellectual Property
Ferring Pharmaceuticals
Paki Banky
Senior IP Counsel (IP Lead Cell & Gene)
Novartis
Corinna Sundermann
Senior Vice President Intellectual Property
Fresenius Kabi
Frank Landolt
Chief Counsel IP & Legal
Confo Therapeutics
Frank Landolt is Chief Counsel, Intellectual Property and Legal at Confo Therapeutics, a privately held biopharmaceutical start-up based in Ghent, Belgium specializing in GPCR-targeted therapeutics.
After studying chemistry and law at the University of Leiden in the Netherlands, Frank worked for almost ten years on pharmaceutical and biotechological patents and licensing in private practice in the Netherlands, where his clients included major pharmaceutical companies as well as some of the top biotech firms and research institutions in the Netherlands.
Prior to joining Confo in 2018, Frank worked for fifteen years in Ablynx N.V. (now a wholly owned Sanofi company), where he was a member of the management team and headed an integrated IP and legal group of four lawyers and five patent professionals. At Ablynx, Frank was involved in negotiating Ablynx’s strategic partnerships and licensing deals with AbbVie, Boehringer-Ingelheim, MSD, Merck-Serono, Novartis, Novo Nordisk, Sanofi and Wyeth.
From 2000 to 2004, Frank was director of IP and legal counsel at Devgen N.V. (now part of Syngenta), another Ghent-based biotechnology company, where he was involved in negotiating Devgen’s strategic collaborations with Sumitomo, Monsanto and DuPont Pioneer.
Frank is a Dutch and European patent attorney, and also holds a degree in business law from the University of Antwerp. He is a member of the Dutch association of patent attorneys (where he is a tutor for the professional qualification course), EPI and LES Benelux (where he is involved in the LES Licensing Course). He is a regular speaker on a range of topics relating to IP and licensing in the (bio)pharmaceutical sector. Frank was named as one of Managing IP’s ‘Corporate IP stars’ for four years in a row (2015-2018).
Guido Pontremoli
Coporate IP Patent Director
Chiesi
Currently employed as global Head of the IP department-Patent at Chiesi Farmaceutici SpA, managing and coaching a team of experienced patent attorneys, patent searchers and administrators, working on the protection, enforcement, litigation and/or opposition of the Chiesi IP, aligned with business decisions.
Before joining Chiesi, I worked in IP groups of big pharma companies (GSK Vaccine, and Bracco Imaging) as senior patent attorney responsible for all the IP aspects concerning some key R&D projects. I also had experience as patent counsel in private practices, dealing with pharma, chemical and bio entities.
Graduated in chemistry from the Univ of Milan, with a PhD in medicinal chemistry and a post-doc experience in USA, I am qualified EPA and chartered Italian patent attorney.
Kristin Cooklin
Head of IP
Zentiva
Toni Santamaria
Vice President Intellectual Property
Adalvo
Toni has been leading the Intellectual Property team at Adalvo since 2021. He has more than 20 years of experience in different pharmaceutical companies where he has been involved in developing and implementing complex patent and data exclusivity litigation strategies for several generics and added value products, including leading parallel litigation cases in multiple European countries. He also has experience in patent and trademark prosecution.
Toni qualified as European Patent Attorney in 2010 and holds a PhD in Organic Chemistry.
Shohta Ueno
Assistant General Counsel - Dispute Resolution
Regeneron
IN PARTNERSHIP WITH
Platinum Partners
Fish & Richardson
Website: https://www.fr.com/industries/life-sciences/
Fish & Richardson has represented pioneering life science innovators from our earliest days. We work closely with life sciences companies to help them achieve their strategic IP goals through acquisition, partnering, licensing, financing, and enforcement. We do this by bringing a unique holistic approach to our clients’ IP matters, fostered by the collaboration between our patent prosecution, litigation, and regulatory practices. We have helped our clients build valuable patent portfolios worth billions of dollars, score big victories at the Patent Trial and Appeal Board (PTAB), and win bet-the-company cases in court. When life sciences clients come to Fish to build an IP strategy, they know that we will leave no stone unturned when crafting creative and comprehensive solutions to maximize the value of their IP.
Gowling WLG
Website: https://gowlingwlg.com/
With more than 1,500 legal professionals in offices worldwide, Gowling WLG offers clients a comprehensive suite of sector-focused legal services. With an award winning global intellectual property practice, our full service firm stands out for its ability to provide support for the full life cycle of a smart idea.
Trade secret protection is an important part of this offering with services spanning multiple disciplines – from the development of trade secrets and data protection policies, to the drafting of NDAs and employment contracts, through to cybersecurity risk management and high stakes litigation.
Whether you are looking to identify and protect your trade secrets to avoid leakage, establishing the value of your intangible assets for merger or acquisition or pursuing a trade secret thief, we can help guide you through trade secrets law around the world and across a number of key sectors. Learn more
Hoyng Rokh Monegier
Website: https://www.hoyngrokhmonegier.com/
Please visit our website for more information.Pinsent Masons
Website: https://www.pinsentmasons.com/
Pinsent Masons international Life Sciences practice is one of the best in Europe.
Their team, comprising more than 100 sector specialists, many of whom are leading individuals in their field with relevant scientific degrees (some to Ph.D.) and experience, drawn from industry, is dedicated to helping their clients continue to develop cutting-edge strategies that use the law as a business enabler to positively impact their bottom line.
The team acts for businesses globally on complex market shifting transactions; cutting edge R&D collaboration; partnering and licensing deals; the most high profile, business-critical patent and regulatory litigations; and hugely impactful anti-trust investigations and litigations.
Comprising some of the world’s leading life sciences experts, the team works with senior management and in-house legal teams to navigate complex regulatory environments, develop effective risk management strategies, and spot and convert opportunities.
Schertenleib Avocats
Website: https://schertenleib-avocats.com/en/equipe/denis-schertenleib/
Please visit our website for more information.Gold Partners
Barnes And Thornbug LLP
Website: https://btlaw.com/
Intellectual Property
Barnes & Thornburg’s Intellectual Property Department, with more than 130 attorneys and professionals, is one of the largest intellectual property practice groups found in a full-service law firm. Our practice covers a broad spectrum of services, including strategic IP portfolio services, prosecuting and litigating patents, trademarks and copyrights, enforcement of patents and trademarks, and defense of IP enforcement actions.
Our IP practice advises and helps a diverse and multinational roster of clients. From electrical and mechanical engineering, to chemistry and microbiology, to computer technology and business methods – our attorneys’ background and experience in several technical disciplines positions us to meet a variety of sophisticated business and inventorship needs.
Life Sciences
Barnes & Thornburg provides a wide range of interdisciplinary legal services to organizations engaged in biotechnology, pharmaceuticals, medical and laboratory devices, health services and bioinformatics. Most of the lawyers in our biotech practice have educational and practical research experience pertinent to the biotechnology industry and many hold advanced degrees in organic chemistry, pharmacology, molecular biology, genetics, immunology and microbiology. We understand chemistry, biotech, pharmaceutical, and medical device technologies. In addition, our intellectual property practice includes professionals with advanced degrees in molecular biology, chemistry, organic chemistry, biochemistry, genetics, biology, pharmacology, immunology, microbiology, biotechnology, bioengineering, physics, mechanical engineering, electrical engineering, industrial engineering, and civil engineering.
Our team represents a wide array of clients in this industry – from startups to Fortune 500 companies. Some of our representative clients include 3M Company, DePuy Orthopaedics, Inc., Eli Lilly and Company, Johnson & Johnson, H.D. Smith Wholesale Drug Co., Hillenbrand, \
Carpmaels & Ransford
Website: https://www.carpmaels.com/
Carpmaels & Ransford LLP is a leader in the European IP market, having driven innovation in the industry for over 200 years. The firm advises clients on all aspects of intellectual property, including drafting, filing and prosecuting patent and trademark applications; drafting and negotiating licence agreements and other commercial IP agreements; advising on the transfer of property rights; assisting clients with patent restoration matters; and conducting enforcement and revocation litigation.
The firm has one of Europe’s largest IP teams serving blue-chip clients across the globe, including Johnson & Johnson, Bristol Myers Squibb, Novartis, Ionis Pharmaceuticals, Mars, Gilead, Raytheon, Regeneron, Takeda, Allergan and Xeros. The firm’s attorneys have considerable technical knowledge, bringing together experience from industry-leading companies, academic research at leading universities and extensive patent expertise in the areas of pharmaceuticals, biotechnology, engineering, tech, chemistry, materials, supplementary protection certificates and information and communication technologies and standards.
Through its fully integrated dispute resolution and transactions teams, the firm is able to provide a holistic service to clients which supports their IP needs from inception to commercialisation. The dispute resolution team, made up of experienced solicitors, barristers and patent attorney litigators, represents clients at all levels of the European Patent Office. The team is also adept at conducting enforcement litigation and revocation actions before the UK Intellectual Property Office and patent, copyright, trademark and other IP litigation in the English courts and the Court of Justice of the European Union, often advising in cases where parallel or related litigation is ongoing in courts across Europe or in the United States.
As a European IP firm with litigators and patent attorneys under one roof, Carpmaels & Ransford is looking forward to offering clients the chance to both obtain UPs using the existing EPO procedure and enforce their patents across Europe in the UPC.
DERIS
Website: https://www.deris.com/
Deris is a one-stop shop for IP services with one of the largest and internationally regarded IP prosecution and advisory team.
We have been the pioneer in shaping the IP landscape by obtaining the precedent decisions & participating the preparation of the IP legislation upon the invitation of the legislative bodies. We provide a wide spectrum of high-quality services that are essential for securing, maintaining and enforcing IP rights.
Our services and counseling are supported by the trademark attorneys and technical experts, who are national and European patent attorneys, under a unique service approach combining longstanding enforcement experience with prosecution-technical expertise. Our goal is to secure enforceable IP rights in the market so that they can be transformed into sustainable commercial values.
EIP
Website: https://www.eip.com/uk/
EIP specialises in high-value and complex patent matters. Our multidisciplinary team combines patent attorneys, litigators and commercial IP lawyers, and we have specialists in three of the world’s main patent markets - Germany, UK and US, and now also in the Nordics through our recent expansion into Sweden.
The benefit of this combination is well illustrated by EIP’s successful representation of clients in high stakes patent litigation before the UK High Court, Court of Appeal and Supreme Court and before the German District and Federal Courts.
Our contentious expertise extends to conducting offensive and defensive oppositions before the European Patent Office, often involving multiple parties and relating to cutting edge platform technologies, to representing clients in national litigation proceedings in the UK and Germany, and since 1 June 2023, also the UPC.
Our litigation practice has built an enviable reputation for quality and success amongst its competitors and clients, with a strong track record including a landmark ruling on Standard Essential Patents (SEPs) from the UK Supreme Court. Our patent attorneys work hand-in-hand with the litigation team in the UK and Germany, to provide technical expertise and put forward the very best case on large scale international patent litigation matters.
In addition to our existing UK, German and Swedish capabilities, EIP Amar, an alliance between EIP and Amar Goussu Staub in Paris, is a dedicated, experienced and technically skilled team of patent litigation specialists created to support clients in any high-stakes litigation before the UPC.
EIP is increasingly involved in advisory and strategic project work in relation to the enforcement of patent rights, including portfolio analyses, infringement and validity analyses and claim charting, and strategic IP advice such as due diligence related to acquisitions and joint ventures.
EIP’s Life Sciences team offers multi-qualified and multi-disciplinary teams to suit the specific needs of each client. Innovations in this sector are increasingly intersectional and, by bringing together life sciences expertise with EIP’s long established strengths in areas such as artificial intelligence and machine learning, our team provides an inter-disciplinary life sciences offering that keeps pace with such innovations.
Gemini Law
Website: http://www.geminilaw.com/
Gemini attorneys are among the most experienced and successful at helping manufacturers of biopharma products navigate IP barriers to access the U.S. market. Gemini has particular expertise in patent strategy and litigation relating to biosimilar, biobetter, generic and 505(b)(2) products, as well as collateral issues concerning the Hatch Waxman and BPCIA regulatory schemes. Gemini is also very experienced in counseling early-stage biotech companies to optimize patent portfolios and mitigate the risk posed by competitors’ IP, as well as IP issues related to licensing and development transactions. Gemini offers “end to end” counseling on IP issues in support of biopharma product development and launch in the U.S., including:
- Litigation risk mitigation and avoidance
- Patent & trade secret design-around strategies
- Patent portfolio optimization
- Biosimilar (BPCIA) litigation & regulatory strategy
- Hatch Waxman litigation & regulatory strategy
- "Biobetter" & "fast follow-on" product litigation & regulatory strategy
- Pharmaceutical device-related litigation & regulatory strategy
- IP & regulatory issues concerning healthcare AI
- CREATES Act requests & litigation
- Section 1782 discovery requests for use in foreign litigation
- Global coordination of litigation strategy concerning biosimilar, generic and biobetter products
- Patent landscaping and freedom-to-operate opinions
- IP-related licensing, development & manufacturing transactions
- Lobbying and legislative initiatives relating to the BPCIA and Hatch Waxman laws
Marks & Clerk
Website: https://www.marks-clerk.com/
Marks & Clerk is an international law firm specialising in intellectual property (IP) law. With a vast network of over 650 professionals across the world, including a qualified team of experienced patent and trademark associates, the firm offers comprehensive technical expertise covering all aspects of intellectual property matters, such as patents, trademarks, designs and copyright. Its services encompass worldwide protection, portfolio management, strategic advice, commercial guidance, licensing, enforcement, clearance and searches, validity and infringement opinions, due diligence and litigation. Operating through a network of offices in Canada, Europe and Asia, Marks & Clerk consistently delivers high-quality, seamless and cost-effective services to clients both locally and globally.
Pearce IP
Website: https://www.pearceip.law/
Pearce IP is a boutique firm offering intellectual property specialist lawyers, patent attorneys and trade mark attorneys to the life sciences industries (in particular, pharmaceutical, biopharmaceutical, biotech, ag-tech and food tech). Pearce IP is recognised by MIP has the only leading regional IP firm with a female founder, and is certified by WEConnect International as women owned. Pearce IP is the 2021 ‘Intellectual Property Team of the Year’ (Lawyers Weekly Australian Law Awards) and was shortlisted for the same award in 2022. Pearce IP is ranked in IAM Patent 1000 and Managing IP (MIP) IP Stars, in Australasian Lawyer 5 Star Awards as a ‘5 Star’ firm, and the Legal 500 APAC Guide for Intellectual Property.
Our leaders have been recognised in virtually every notable IP listing for their legal, patent and trade mark excellence including: IAM Patent 1000, MIP IP Stars, Doyles Guide, WIPR Leaders, 5 Star IP Lawyers, Best Lawyers, and Australasian Lawyer 5 Star Awards, and have been honoured with many awards including Australian Law Awards – IP Partner of the Year, Women in Law Awards – Partner of the Year, Women in Business Law Awards - Patent Lawyer of the Year (Asia Pacific), Most Influential Lawyers (Changemaker), among other awards.
Reddie & Grose
Website: https://www.reddie.co.uk/
Reddie and Grose is a European IP firm with offices in London, Munich and Cambridge. Our life sciences team is made up of specialist hubs that allow us to offer tailored services across the entire IP spectrum. This blend of specialism and diversity is recognised as one of our key strengths.
Our biotech hub is based out of our Cambridge office and has decades of experience taking clients from university spin-off to IPOs, as well as being experts in obtaining plant variety protection. Our London team specialises in managing the global patent portfolios and supplementary protection certificate strategies of multi-national companies based in the UK and Europe. In Munich, the team focuses on contentious pharmaceutical cases, regularly representing clients in EP opposition proceedings and advising on European product launch and litigation strategies.
Combining all this knowledge ensures that are clients will always benefit from rounded, commercially aware, advice of the highest standard.
Trevisan & Cuonzo
Website: https://www.trevisancuonzo.com/en/index.html
Please visit our website for more information.Solutions Partner
Conference Packages
Sending Your Team? Group Discounts Available!
Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates
Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off
If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920
We accept the following cards through Stripe:
Ticket price will increase in
— —
Friday, July 28, 2023 to Friday, August 18, 2023
Tier 1 - In-House
€799
Pre-Launch Rate (Register Before 18 August & Save €800)
Exclusively for Pharma and Biotech
2 Day In-Person Conference Pass
You can add our pre-day event as an add-on during registration
Saturday, August 19, 2023 to Saturday, September 30, 2023
Tier 1 - In-House
€999
Super Super Early Bird rate (Register Before 29 September & Save €600)
Exclusively for Pharma and Biotech
2 Day In-Person Conference Pass
You can add our pre-day event as an add-on during registration
Sunday, October 1, 2023 to Friday, November 3, 2023
Tier 1 - In-House
€1199
Super Early Bird rate (Register Before 3 November & Save €400)
Exclusively for Pharma and Biotech
2 Day In-Person Conference Pass
You can add our pre-day event as an add-on during registration
Saturday, November 4, 2023 to Friday, December 8, 2023
Tier 1 - In-House
€1399
Early Bird rate (Register Before 8 December & Save €200)
Exclusively for Pharma and Biotech
2 Day In-Person Conference Pass
You can add our pre-day event as an add-on during registration
Saturday, December 9, 2023 to Wednesday, January 24, 2024
Tier 1 - In-House
€1599
Standard Rate
Exclusively for Pharma and Biotech
2 Day In-Person Conference Pass
You can add our pre-day event as an add-on during registration
Saturday, July 29, 2023 to Friday, August 18, 2023
Tier 2 - Law Firms
€1699
Pre-Launch Rate (Register Before 18 August & Save €1000)
Exclusively for Law firms focusing on Life Sciences & Intellectual Properties Providers Pricing
2 Day In-Person Conference Pass
You can add our pre-day event as an add-on during registration
Saturday, August 19, 2023 to Saturday, September 30, 2023
Tier 2 - Law Firms
€1899
Super Super Early Bird rate (Register Before 29 September & Save €800)
Exclusively for Law firms focusing on Life Sciences & Intellectual Properties Providers Pricing
2 Day In-Person Conference Pass
You can add our pre-event workshop as an add-on during registration
Sunday, October 1, 2023 to Friday, November 3, 2023
Tier 2 - Law Firms
€2299
Super Early Bird rate (Register Before 3 November & Save €400)
Exclusively for Law firms focusing on Life Sciences & Intellectual Properties Providers Pricing
2 Day In-Person Conference Pass
You can add our pre-event workshop as an add-on during registration
Saturday, November 4, 2023 to Friday, December 8, 2023
Tier 2 - Law Firms
€2499
Early Bird rate (Register Before 8 Decemeber & Save €200)
Exclusively for Law firms focusing on Life Sciences & Intellectual Properties Providers Pricing
2 Day In-Person Conference Pass
You can add our pre-event workshop as an add-on during registration
Saturday, December 9, 2023 to Wednesday, January 24, 2024
Tier 2 - Law Firms
€2699
Standard Rate
Saturday, July 29, 2023 to Friday, August 18, 2023
Tier 3 - Vendors
€2199
Pre-Launch Rate (Register Before 18 August & Save €800)
Exclusively for Solution Providers
2 Day In-Person Conference Pass
You can add our pre-event workshop as an add-on during registration
Saturday, August 19, 2023 to Saturday, September 30, 2023
Tier 3 - Vendors
€2399
Super Super Early Bird rate (Register Before 29 September & Save €600)
Exclusively for Solution Providers
2 Day In-Person Conference Pass
You can add our pre-event workshop as an add-on during registration
Sunday, October 1, 2023 to Friday, November 3, 2023
Tier 3 - Vendors
€2599
Super Early Bird rate (Register Before 3 November & Save €400)
Exclusively for Solution Providers
2 Day In-Person Conference Pass
You can add our pre-event workshop as an add-on during registration
Saturday, November 4, 2023 to Friday, December 8, 2023
Tier 3 - Vendors
€2799
Early Bird rate (Register Before 8 December & Save €200)
Exclusively for Solution Providers
2 Day In-Person Conference Pass
You can add our pre-event workshop as an add-on during registration
Saturday, December 9, 2023 to Wednesday, January 24, 2024
Tier 3 - Vendors
€2999
Standard Rate
Exclusively for Solution Providers
2 Day In-Person Conference Pass
You can add our pre-event workshop as an add-on during registration
Friday, July 28, 2023 to Monday, January 22, 2024
UPC Forum 2024 (22 January)
€899
Develop a Pan-European litigation strategy Industry-led panel sessions focusing patent value and the UPC from a cross-industry perspective
Understand the decision making process of the people behind the new system with a cross-industry judicial panel session
Gain a practical and in-depth understanding of UPC litigation practice with a mock trial focusing on the central themes of the new court
Preparing registration...
About Kisaco Research
Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.
Meet industry peers that will help build a career-changing network for life.
Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.
Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.
Invest both in your company growth and your own personal development by signing up to one of our events and get started.
We'd love to hear from you.
Contact us at +44 (0)20 3696 2920 and email [email protected], or let us know what subject area you're interested in below.